Henan Cancer Hospital

XPO1-mediated TRIM21 nuclear export reprograms TREM2+ macrophage polarization by targeting IRF3 to augment anti-PD-1 efficacy in small cell lung cancer

Abstract Small cell lung cancer (SCLC) is an aggressive malignancy that responds poorly to immune checkpoint inhibitor (ICI) therapy, due to its immunosuppressive tumor microenvironment. Here, we analyse preclinical mouse tumor models and patient-derived SCLC samples and identify...

P1.083. Sequential Versus Concurrent Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized, Controlled, Open-Label, Phase II Trial

Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Neoadjuvant chemotherapy combined with PD-1 inhibitors has application potential for locally advanced esophageal squamous cell carcinoma (ESCC), but there is no prospective evidence for the optimal t...

Multi-omics profiling reveals gene signatures and therapeutic targets in HER2-guided gastric cardia adenocarcinoma patients

Abstract Therapeutic targets for gastric cardia adenocarcinoma (GCA), particularly for HER2-negative patients, are lacking. Here, we conducted multi-omics profiling on 128 GCA patients using mass spectrometry, whole-exome sequencing, RNA-Seq, scRNA-Seq and spatial transcriptomics...

Fuzuloparib in combination with apatinib versus fuzuloparib alone for recurrent ovarian cancer: a randomized, open-label, phase 2 trial

A randomized, open-label, phase 2 trial assessed fuzuloparib (a PARP inhibitor) plus apatinib (a vascular endothelial growth factor receptor [VEGFR] inhibitor) versus fuzuloparib alone in patients with recurrent ovarian cancer (ROC). Patients with ROC who had failed ≥ 2 lines of...

CACA guidelines for the management of adult cancer pain

Abstract Cancer pain, one of the most prevalent and distressing symptoms in cancer patients, is closely associated with cancer diagnosis, therapeutic interventions, quality of life, and survival outcomes. Effective cancer pain management requires multidisciplinary collaborative a...

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Mefatinib, a novel second-generation epidermal growth factor (EGFR) tyrosine kinase inhibitor that has shown promising antitumor activity in targeting non-small cell lung cancer (NSCLC) with common and uncommon EGFR- activating mutations. In this phase III, randomized, double-bli...

Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations

Importance: Combination therapy has emerged as a promising therapeutic approach for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, its clinical benefit-risk profile remains a focus of ongoing debate. Identifying patients...

Lysosome‐Targeted Self‐Adjuvanting Ammonia Nanogenerator Potentiates Hepatocellular Carcinoma Immunotherapy via Ammonia Death

ABSTRACT Ammonia death is a recently identified form of regulated cell death with unique molecular mechanisms and prominent anticancer activity. Nevertheless, its efficacy is severely restricted by the absence of tumor‐targeted ammonia delivery vehicles and poorly defined immunog...

Macrophage-to-myofibroblast transition-derived itaconate promotes bone metastasis in lung cancer through targeting of HSPA8

Abstract Lung cancer bone metastasis carries a poor prognosis, yet the metabolic determinants driving tumour–stroma crosstalk remain largely elusive. Despite extensive investigations into itaconate, a prominent immunometabolite implicated in macrophage polarization, the precise m...